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supplement increases circulating free fatty acids
and energy expenditure in human subjects
Sang-Rok Lee, JohnHenry M Schriefer, Trint A Gunnels, Innocence C Harvey and Richard J Bloomer*Abstract
Background: Higenamine, also known as norcoclaurine, is an herbal constituent thought to act as a beta-2
adrenergic receptor agonist—possibly stimulating lipolysis. It was the purpose of this study to determine the
impact of a higenamine-based dietary supplement on plasma free fatty acids and energy expenditure following
acute oral ingestion.
Methods: Sixteen healthy subjects (8 men; 26.1 ± 2.5 yrs; 8 women 22.4 ± 3.1 yrs) ingested a dietary supplement
containing a combination of higenamine, caffeine (270 mg), and yohimbe bark extract or a placebo, on two
separate occasions in a double-blind, randomized, cross-over design, separated by 6–8 days. Blood samples were
collected immediately before ingestion, and at 30, 60, 120, and 180 minutes post ingestion, and analyzed for
plasma free fatty acids (FFA) and glycerol. Breath samples were collected at the same times for a measure of
kilocalorie expenditure and respiratory exchange ratio (RER) using indirect calorimetry. Heart rate and blood
pressure were recorded at all times. Data collection occurred in the morning following a 10 hour overnight fast.
Results: A condition effect was noted for both FFA (p < 0.0001) and kilocalorie expenditure (p = 0.001), with values
higher for supplement compared to placebo at 60, 120, and 180 minutes post ingestion. No statistically significant
effects were noted for glycerol or RER (p > 0.05). A condition effect was noted for heart rate (p = 0.03) and systolic
blood pressure (p < 0.0001), with values higher for supplement compared to placebo.
Conclusion: Ingestion of a higenamine-based dietary supplement stimulates lipolysis and energy expenditure, as
evidenced by a significant increase in circulating FFA and kilocalorie expenditure. The same supplement results in a
moderate increase in heart rate (~3 bpm) and systolic blood pressure (~12 mmHg), which is consistent with
previous studies evaluating moderate doses of caffeine and yohimbine, suggesting that higenamine contributes
little to the increase in these hemodynamic variables. These findings are in reference to young, healthy and active
men and women.
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Obesity has grown to epidemic proportions in recent
years, with an estimated one-third of adults in the
United States being diagnosed as obese [1]. Ideal treat-
ment for this disease includes appropriate dietary intake
[2], coupled with regular physical activity [3] and struc-
tured exercise [4]. In some cases, the use of selected* Correspondence: rbloomer@memphis.edu
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reproduction in any medium, provided the ordietary supplements may assist in weight lost, as many
have shown promise with regards to decreasing appetite
[5-7], stimulating lipolysis [8-10], and increasing energy
expenditure [8,9,11,12].
Related to the latter, caffeine is likely the most widely
used dietary ingredient within weight loss supplements.
A naturally occurring crystalline xanthine alkaloid, caf-
feine is regularly consumed by humans from around the
world—being contained within beverages (e.g., coffee,
tea, energy drinks) and dietary supplements, as well as
medications. In addition to providing a short-term. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of 8 men and 8 women
Variable Men Women
Age (yrs)* 26.1 ± 2.5 22.4 ± 3.1
Height (cm)* 176.1 ± 6.7 165.3 ± 6.1
Weight (kg)* 80.2 ± 11.9 62.0 ± 7.9
BMI (kg∙m-2)* 25.8 ± 3.5 22.6 ± 2.2
Waist (cm)* 82.8 ± 7.3 68.5 ± 4.6
Hip (cm) 101.7 ± 4.9 97.6 ± 4.3
Waist:Hip* 0.81 ± 0.05 0.70 ± 0.03
Years anaerobic exercise training 8.6 ± 7.9 3.9 ± 3.3
Hours per week anaerobic exercise 2.7 ± 2.8 1.9 ± 1.2
Years aerobic exercise training 10.0 ± 5.5 8.0 ± 5.4
Hours per week aerobic exercise 4.0 ± 2.9 4.2 ± 2.3
Data are mean ± SD.
*men different than women (p < 0.05).
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tention due to their potential health-related properties.
Particularly, caffeine contributes to improving metabolic
capacity and may ameliorate risk factors related to obes-
ity [13] and type-2 diabetes mellitus [14]. While caffeine
alone may have beneficial effects and is generally well-
tolerated, other ingredients are often looked to in an at-
tempt to enhance the lipolytic and thermic effects of
caffeine.
One such ingredient is yohimbe bark extract, an
herbal agent found naturally in Pausinystalia yohimbe
(Yohimbe), Rauwolfia serpentina (Indian Snakeroot),
and Alchornea floribunda (Niando) [15,16]. While yo-
himbe has been used for many years to treat sexual dys-
function in men, more recently, it has been reported
that yohimbine, present within yohimbe bark, promotes
an improvement in lipid mobilization and thermogen-
esis. Specifically, yohimbine has been shown to stimu-
late lipid mobilization in normal weight [17] and obese
[18] individuals. Further, an animal study demonstrated
that yohimbine administration increased energy ex-
penditure in dogs, suggesting this agent as a mediator
for increased thermogenesis [19].
One additional herbal agent that is beginning to receive
attention within the dietary supplement community is
higenamine, which is found naturally in a variety of plants
including Nelumbo nucifera (lotus seeds), Nandina
domestica (fruit), Aconitum carmichaelii (root), Asarum
heterotropioides, Galium divaricatum (stem and vine),
and Annona squamosa. Higenamine, 1-benzyl-1,2,3,4-
tetrahydroisoquinoline alkaloid, has been used as a cardiac
stimulant through chronotropic and inotropic action. This
plant-based agent has been applied using a phar-
macological approach in an attempt to improve cardiac
function due to its ability to stimulate beta-adrenergic re-
ceptors (β-AR). It has been reported that β-AR agonists
enhance lipolysis and thermogenesis [19]. Based on this
finding, higenamine, as a potent β-AR agonist, may be
considered an effective anti-obesity agent, if capable of in-
creasing both lipolytic and thermogenic processes.
While certain studies have been conducted to deter-
mine the potential mechanisms of action of higenamine,
we are unaware of any studies involving oral intake of
higenamine by human subjects. Considering that this
ingredient is now making its way into the dietary supple-
ment marketplace, it is of interest to generate data per-
taining to the potential efficacy of this herbal ingredient.
Moreover, it is important to understand the impact of
this agent on the heart rate and blood pressure response
to treatment—as the safety of an herbal preparation
should always be considered before use. Therefore, the
purpose of the present study was to determine the im-
pact of a higenamine-based dietary supplement on
plasma free fatty acids and energy expenditure followingacute oral ingestion, while measuring the heart rate and
blood pressure response to acute oral treatment.Results
Overview: dietary data and subjective response to
supplement and placebo
All 16 subjects successfully completed all aspects of the
study. Subject data are provided in Table 1. Dietary data
were not different between the 24 hours prior to each
condition (p > 0.05). Dietary data are presented in
Table 2. Subjects tolerated the supplement and placebo
conditions well. As expected, selected subjects reported
feeling “stimulated” approximately one hour following
ingestion of the supplement. That said, no subject expe-
rienced an adverse event, with only moderate increases
in both heart rate and blood pressure noted (as indicated
below; see also Table 3).Biochemical data
Regarding FFA, a condition effect was noted (p < 0.0001),
with values higher for the supplement compared to pla-
cebo. A time effect was also noted (p = 0.0009), with values
higher at 60 minutes, 120 minutes, and 180 minutes com-
pared to 30 minutes; values were also higher at 180 minutes
compared to pre. An interaction effect was noted (p =
0.05). Contrasts revealed significant differences between
supplement and placebo at 60 minutes (p = 0.0004),
120 minutes (p = 0.0004), and 180 minutes post ingestion
(p = 0.004). Regarding glycerol, no condition (p = 0.20),
time (p = 0.27), or interaction (p = 0.72) effects were noted.
Data for FFA and glycerol are presented in Figure 1. Men
and women responded in a similar manner to supplement
and placebo with regards to FFA and glycerol.
Table 2 Dietary data of 16 subjects during the 24 hour
period before ingestion of supplement or placebo
Variable Supplement Placebo
Kcal 2202 ± 199 2177 ± 225
Protein (g) 100 ± 13 99 ± 15
Carbohydrate (g) 254 ± 26 251 ± 27
Fat (g) 82 ± 12 83 ± 11
Vitamin C (mg) 135 ± 42 129 ± 34
Vitamin E (mg) 14 ± 3 11 ± 3
Vitamin A (RE) 518 ± 173 320 ± 74
Data are mean ± SEM.





















































Figure 1 Plasma free fatty acids (A) and glycerol (B) before and
following ingestion of supplement or placebo. Data are mean ±
SEM. *Condition effect noted for free fatty acids (p < 0.0001). **Time
effect noted for free fatty acids (p = 0.0009); values higher at 60 min,
120 min, and 180 min compared to 30 min; values higher at
180 min compared to pre. †Difference noted at 60 min (p = 0.0004),
120 min (p = 0.0004), and 180 min (p = 0.004) between supplement
and placebo. Interaction effect noted for free fatty acids (p = 0.05).
No statistically significant effects noted for glycerol (p > 0.05).
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Regarding kilocalorie expenditure, a condition effect was
noted for kilocalorie expenditure (p = 0.001). No time (p =
0.12) or interaction (p = 0.32) effects were noted for kilocal-
orie expenditure. Contrasts revealed significant differences
between supplement and placebo at 60 minutes (p = 0.03)
and 120 minutes (p = 0.02) post ingestion. A trend for a dif-
ference was noted at 180 minutes (p = 0.07) post ingestion.
Regarding RER, no condition (p = 0.81), time (p = 0.08), or
interaction (p = 0.42) effects were noted. Data for kilocal-
orie expenditure and RER are presented in Figure 2. As
expected, energy expenditure for women was lower than
for men (sex effect: p < 0.0001), while the RER was not
different between men and women (sex effect: p = 0.27).
Heart rate and blood pressure data
For both heart rate (p = 0.03) and systolic blood pres-
sure (p < 0.0001), a condition effect was noted, with
values higher for supplement compared to placebo. No
time (p = 0.98) or interaction (p = 0.76) effects were
noted for heart rate. No time (p = 0.29) effect was noted
for systolic blood pressure; however an interaction effect
was noted (p = 0.03). Regarding diastolic blood pressure,
no condition (p = 0.11), time (p = 0.90), or interaction
(p = 0.88) effects were noted. Data for heart rate and
blood pressure are provided in Table 3. The overall heart
rate for women was slightly higher than for men (sex ef-













Pre 63 ± 3 64 ± 3 112 ± 2 110 ± 2 66 ± 2 64 ± 2
30 min 62 ± 3 62 ± 2 116 ± 3 109 ± 2 68 ± 2 66 ± 2
60 min 65 ± 4 61 ± 2 124 ± 3 106 ± 3 70 ± 2 65 ± 2
120 min 66 ± 4 60 ± 2 122 ± 3 111 ± 2 69 ± 2 66 ± 3
180 min 66 ± 4 60 ± 2 119 ± 3 112 ± 3 67 ± 2 66 ± 3
Data are mean ± SEM.
*Condition effect noted for heart rate (p = 0.03) and systolic blood pressure ( <0.0001). Interaction effect noted for systolic blood pressure (p = 0.03). No other






















































Figure 2 Kilocalorie expenditure (A) and respiratory exchange ratio (B) before and following ingestion of supplement or placebo. Data
are mean ± SEM. *Condition effect noted for kilocalories (p = 0.001). †Difference noted at 60 min (p = 0.03) and 120 min (p = 0.02) between
supplement and placebo; trend for a difference noted at 180 min (p = 0.07). No other statistically significant effects noted for kilocalories or for
respiratory exchange ratio (p > 0.05).
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respectively).
Discussion
The present study documents for the first time the im-
pact of an orally administered higenamine-based dietary
supplement on measures of lipolysis and metabolic rate
in a sample of human subjects. Our data indicate that
when combined with caffeine and yohimbe bark extract,
higenamine increases both lipolysis and energy expend-
iture, as evidenced by a significant increase in circulating
FFA and kilocalories. These findings are in reference to
young, healthy and active men and women. Future stud-
ies may include a sample of older, overweight, and/or in-
active individuals to determine if similar results are
observed—in particular when considering that such indi-
viduals might be consumers of weight loss dietary sup-
plements containing higenamine.
From a mechanistic point of view, caffeine is known
to stimulate lipolysis in a variety of ways. One of the
plausible mechanisms is that caffeine may reduce
the degradation of cyclic adenosine monophosphate
(cAMP) and increase cAMP production as well via β-
AR independent and dependent pathways [20]. The in-
dependent effects may be due to the observation that
caffeine appears to antagonize adenosine receptors and
also inhibits the activation of phosphodiesterase, which
stimulates cAMP degradation [21]. Caffeine also in-
duces an elevation in catecholamine release, which may
be secondary to the adenosine blockade [20]. Taken to-
gether, caffeine may enhance lipid mobilization, which
may have implications for helping to control the onset
and progression of obesity.
Although not as well described in the literature, yo-
himbe bark extract has also been reported to increaselipolysis. Yohimbine, known as an alpha2-adrenoreceptor
(α2-AR) antagonist, may contribute to enhancing lipid
mobilization. Since α2-AR functions as an anti-lipolytic
mediator, the ability of yohimbine to block α2-AR on the
fat cells can stimulate fat metabolism. In agreement with
this assertion, Galitzky et al. [19] reported greater plasma
non-esterified fatty acids and energy expenditure after
acute yohimbine ingestion in the dog. This finding agrees
with results from human studies which demonstrated that
yohimbine administration improved lipolytic capacity by
promoting β-AR and inhibiting α2-AR in adipocytes in
healthy [17] and obese [18] individuals.
Studies using caffeine and yohimbe alone have noted
an increase in both markers of lipolysis and metabolic
rate. In relation to caffeine use, Rumpler and colleagues
[22] found that caffeine treatment (270 mg) enhanced
fat oxidation by 8% in men, while increasing energy ex-
penditure by 331 kJ (3.4%). In relation to yohimbe use,
yohimbine consumption (0.2 mg∙kg-1) increased nor-
epinephrine approximately 40 to 50%, resulting in ele-
vated lipolysis by stimulating β-AR in healthy men [17].
However conflicting data indicate no effect of yohimbine
administration on lipolysis [23].
Higenamine has been investigated recently and is be-
ginning to receive attention as a dietary ingredient for
inclusion within weight loss supplements. Higenamine
has been used to improve cardiovascular and respira-
tory disease due to its ability as a β-AR agonist. How-
ever, to our knowledge, no study has reported pro-
lipolytic and/or -thermogenic properties of higenamine
alone or combined with other ingredients in humans.
We observed a significant increase in lipolysis and
thermogenesis, noted as greater plasma FFA and energy
expenditure in the supplement group compared with
the placebo group. As previously mentioned, β-AR
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lating related signaling pathways.
While caffeine can increase metabolic rate and may have
lipolytic potential, some studies indicate that caffeine does
not contribute to lipolysis. For example, Bracco et al. [24]
reported that while caffeine (1248 mg∙d-1 for lean;
1604 mg∙d-1 for obese) increased energy expenditure by
728 kJ (7.6%) and 410 kJ (4.9%) in lean and obese women,
respectively over 24 hours, it did not increase fat oxidation
in either group. On the other hand, it has been suggested
that caffeine administration combined with other ingredi-
ents may enhance both energy expenditure and lipolysis.
Rumpler and colleagues [22] reported that adult men who
consumed caffeine (270 mg) along with catechins
(662.5 mg) significantly increased both energy expenditure
(2.9%) and fat oxidation (12%) over 24 hours, compared
with 3.4% and 8% for caffeine alone. These findings agree
with more recent work by Rudelle et al. [25] who observed
that combined administration of caffeine (300 mg) and
catechins (540 mg) improved metabolic capacity (4.6%)
and lipolysis (3.5%) in men and women. Further, Dulloo
et al. [26] reported that 150 mg of caffeine ingestion alone
did not increase energy expenditure and lipid mobili-
zation, while caffeine combined with catechin polyphenols
increased energy expenditure by 328 kJ (4%) and fat oxida-
tion by 9.9%.
Considering the reported isolated impact of caffeine
and yohimbe on markers of lipolysis and metabolic rate
(as described above), the inclusion of higenamine in the
tested supplement likely had an impact on both FFA and
kilocalorie expenditure. Of course, future studies should
be designed to deliver each of these three agents inde-
pendently, in order to better understand their isolated
impact on selected measures of lipolysis and metabolic
rate. Our failure to include all three ingredients inde-
pendently is a limitation of the present design.
Based on our findings for increased lipolysis and kilo-
calorie expenditure, it might be hypothesized that the
supplement may aid in body weight/fat loss over time.
When considering the energy expenditure data, the
supplement resulted in an approximate increase of 10
kilocalories per hour over placebo during the post in-
gestion observation period. If this increase persisted,
the increased energy expenditure may translate into
meaningful weight loss over time. It is interesting to
note that values for kilocalorie expenditure were
highest at the 180 minute post ingestion time,
suggesting that the increase may have persisted at times
beyond this point. Our cessation of measurements at
180 minutes post ingestion may be considered a limita-
tion of the present design. Further research is needed
to determine the impact of this supplement on weight/
fat loss when used on a regular basis—possibly in the
context of an acute exercise session, as ingesting thesupplement prior to exercise might make available
more FFAs for oxidation during the actual exercise
session.
If considering long-term treatment with this supple-
ment, it is important to take into account the rise in
heart rate and blood pressure experienced by subjects. As
indicated in Table 3, heart rate and blood pressure (sys-
tolic in particular) were moderately elevated following in-
gestion of the supplement. When compared to use of
caffeine alone (at a dosage of ~250-300 mg; a similar
amount contained within 2–3 cups of coffee), the changes
observed with the supplement are slightly greater. Corti
et al. [27] found that intravenous caffeine administration
(250 mg) significantly increased systolic blood pressure by
3 mmHg and 6.4 mmHg at 30 and 60 minutes. Lane [28]
also reported that caffeine consumption (250 mg) signifi-
cantly increased both systolic and diastolic blood pressure
approximately 7 mmHg and 6 mmHg, respectively.
Hartley and colleagues [29] reported that caffeine con-
sumption (3.3 mg·kg-1) increased both systolic and dia-
stolic blood pressure by 4.5 and 3.3 mmHg in women and
by 4.1 and 3.8 mmHg in men. Similar findings for blood
pressure have been observed with yohimbine administra-
tion, with an increase in mean arterial pressure of 13%
[30] and 16% [31].
Regarding heart rate change, caffeine administration
most often results in either no change or a slight de-
crease in resting heart rate. However, yohimbine ad-
ministration has been noted to induce a heart rate
increase of 8% in healthy individuals [31]. Collectively
considering the above, our observed increase of
~3 bpm in heart rate and ~12 mmHg in systolic blood
pressure may be mostly explained by the combined ad-
ministration of caffeine and yohimbe bark extract.
Interestingly, higenamine administration has been
reported to actually decrease blood pressure in animals
[32], and was concluded to be safe for human intake
following acute intravenous administration [33]. This is
supported by evidence indicating a relatively high lethal
dose (LD50) of 50 mg/kg following higenamine injec-
tion, suggesting less concern for acute toxicity with oral
consumption [34].
With consideration for the above information, future
studies should ideally include the administration of
higenamine alone to determine the influence of this
agent on both heart rate and blood pressure. In fact, fu-
ture work using a wide variety of subjects, coupled with
a broad array of outcome measures would be helpful in
determining the overall safety profile of higenamine and
higenamine-based dietary supplements. For now, it
would be wise for individuals who are hypertensive
(resting blood pressure ≥140/90 mmHg) or for those
who are pre-hypertensive (resting blood pressure ≥120/
80 mmHg) to avoid using any stimulant-based dietary
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individuals should consult with a qualified health care
professional prior to use.
Conclusions
We report that a higenamine-based dietary supplement
stimulates lipolysis and energy expenditure in young and
healthy human subjects. The same supplement results in
a moderate increase in heart rate (~3 bpm) and systolic
blood pressure (~12 mmHg). Because the supplement
contained a combination of higenamine, caffeine, and
yohimbe bark extract, we are uncertain of the exact con-
tribution of each of the three ingredients. Further well-
controlled intervention trials are needed to determine
the chronic effects of the supplement on body weight/fat
loss and associated health related parameters.
Methods
Subjects
Healthy, exercise-trained men (n = 8) and women (n = 8)
were enrolled in this study and completed all aspects of
this work. Prior to participation, subjects completed a
health history and physical activity questionnaire. Subjects
did not have any history of cardiovascular or metabolic
disease, nor did any subject smoke cigarettes. All subjects
were physically active, engaged in regular anaerobic and/
or aerobic exercise. Descriptive characteristics of subjects
are presented in Table 1. The study protocol was approved
by The University of Memphis Institutional Review Board
for Human Subjects Research and subjects provided writ-
ten informed consent prior to participating.
Conditions and lab testing
Following the initial screening procedures, subjects
reported to the lab for testing in the morning hours
(0600–1000), following a 10 hour overnight fast and
without caffeine for the prior 24 hours. Testing was
conducted on two different occasions separated by 6–
8 days. The time of day for testing was matched for each
subject on the two occasions. All procedures, as de-
scribed below, were identical for both test sessions (sup-
plement and placebo). The supplement consisted of a
proprietary combination of higenamine, yohimbe bark
extract, and caffeine (270 mg). The total dosage of each
ingredient was delivered by ingesting two caplets. The
placebo caplets contained microcrystalline cellulose;
subjects also ingested two caplets of the placebo. For
each condition, caplets were dispensed from the same
bottle and were produced in accordance with Good
Manufacturing Practices. Caplets for both conditions
were identical in appearance and the experiment was
conducted as a double blind, randomized, cross-over
design. The investigators did not receive the blinding code
until all data were collected. No food was allowed duringthe three hour post ingestion period. However, water was
allowed ad libitum and was measured and matched for
both days of testing (mean intake for men = 1272 ±
124 mL; mean intake for women = 760 ± 117 mL).
Subjects were asked not to exercise or to perform any
strenuous physical activity for the 48 hours prior to each
test day. Following a minimum10 minute period of quiet
rest, heart rate (via 60 second radial artery palpation)
and blood pressure (via auscultation) were measured, a
blood sample was obtained, and subjects provided a five-
minute breath sample (for analysis of kilocalorie expend-
iture and respiratory exchange ratio [RER]). Subjects
were then provided with their assigned condition and
ingested it in the presence of an investigator. At all other
measurement times (30, 60, 120, and 180 minutes post
ingestion), the same order of collection as described
above was followed. Subjects remained inactive in the la-
boratory during the entire three hour test period and
read, listened to music, watched television, worked on a
computer, etc.
A total of five venous blood samples (~7 mL per sam-
ple) were taken from subjects’ forearm vein via needle
and collection tube (pre ingestion, 30, 60, 120, and
180 minutes post ingestion). Blood was immediately
processed in a refrigerated centrifuge in order to obtain
plasma. The plasma samples were then stored in ali-
quots at −70°C. Assays were performed in duplicate on
first thaw within one month of sample collection. Free
fatty acids were determined using a fatty acid detection
kit (Catalogue # SFA-5; Zen-Bio, Inc.; Research Triangle
Park, NC) following the instructions of the manufac-
turer. Glycerol was determined using the Free Glycerol
Determination Kit (FG0100) and Glycerol Standard
(G7793) following the instructions of the manufacturer
(Sigma Aldrich; St. Louis, MO).
The measurement of kilocalorie expenditure was
performed using indirect calorimetry (Parvo Medics,
TrueOne® 2400). All equipment was calibrated on the
morning of each test day. Total oxygen consumption
(L∙min-1) was determined from gas collection and used
to estimate total kilocalorie expenditure. The RER was
also determined from gas collection data (VCO2/VO2),
and used as a measure of substrate utilization.
Dietary intake
Subjects were asked to record all food and beverage con-
sumed during the 24 hour period prior to each test day.
Subjects were asked to duplicate the food and beverage
intake during the 24 hour periods prior to both test
days, in an attempt to best control for the influence of
acute dietary intake on our outcome measures. Diet re-
cords were analyzed for total kilocalories, protein, carbo-
hydrate, fat, and selected vitamins (Food Processor SQL,
version 9.9, ESHA Research, Salem, OR).
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Data were analyzed using a 2 (condition) by 5 (time)
analysis of variance (ANOVA). Tukey’s post hoc testing
was used when needed. Single degree of freedom con-
trasts were used to investigate differences in FFA and
kilocalorie expenditure between supplement and placebo
at the post ingestion time points. Dietary and subject de-
scriptive data were analyzed using a one-way ANOVA.
All analyses were performed using JMP statistical soft-
ware (version 4.0.3, SAS Institute, Cary, NC). Statistical
significance was set at P ≤ 0.05. The data are presented
as mean ± SEM, except for subject descriptive character-
istics (mean ± SD). Although a comparison between men
and women was not a primary focus of this study, we
did conduct an analysis in which sex was built into the
model. These results are very briefly presented within
the Results section.
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